HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Over The Counter 9 Oct 2023: What’s Going On With Oral Phenylephrine In The US? With HBW’s Malcolm Spicer

Executive Summary

In this episode, HBW Insight speaks to its own OTC expert, managing editor Malcom Spicer, about recent controversy in the US surrounding oral nasal decongestant phenylephrine.

Used widely and safely by US consumers for around a half century, the efficacy of oral phenylephrine has come under question following a 2015 citizen petition by University of Florida pharmaceutical researchers, which asked the FDA to remove the ingredient from the final OTC CCABA monograph. Only recently addressing this petition, prompted by reforms to the US OTC monograph system, an FDA advisory panel has unanimously voted that research the FDA presented during a two-day meeting in September didn’t support oral phenylephrine’s efficacy for nasal decongestion at the CCABA monograph dose of 10mg.

In this podcast, HBW Insight’s US consumer health managing editor Malcolm Spicer draws on his extensive experience and writing on this topic to take listeners beyond the headlines and offers his analysis of this crucial development, which may or may not have wider implications beyond the US. 

Further Reading

Humic Acid Nasal Sprays Recalled During Potential For Sales Boost Due To Phenylephrine Doubts

Message Clear For Xylitol Nasal Spray Firm Xlear: ‘Capitalize’ On FDA’s Oral Phenylephrine Doubts

US Advisory Panel Leaves No Room For Doubt: Oral Phenylephrine Ineffective As Nasal Decongestant

US FDA Rides Different Monograph System In Second Roundup Of Oral Phenylephrine Efficacy

US FDA Finds Phenylephrine Ineffective As Nasal Decongestant, Looks At Removing From Monograph

Further Listening

Citeline podcasts are available on Apple PodcastsGoogle PodcastsSoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Over The Counter Theme Music:

Warm Vacuum Tube by Admiral Bob (c)

Copyright 2019 Licensed under a Creative Commons Attribution (3.0) license

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel